A share price of Verona Pharma Plc ADR [VRNA] is currently trading at $62.01, up 3.23%. An important factor to consider is whether the stock is rising or falling in short-term value. The VRNA shares have gain 7.27% over the last week, with a monthly amount drifted -7.18%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Verona Pharma Plc ADR [NASDAQ: VRNA] stock has seen the most recent analyst activity on April 21, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $80. Previously, ROTH MKM started tracking the stock with Buy rating on January 10, 2025, and set its price target to $68. On October 03, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $50 on the stock. Piper Sandler started tracking with a Overweight rating for this stock on August 26, 2022, and assigned it a price target of $31. In a note dated September 13, 2021, H.C. Wainwright initiated an Buy rating and provided a target price of $25 on this stock.
Verona Pharma Plc ADR experienced fluctuations in its stock price throughout the past year between $11.39 and $70.40. Currently, Wall Street analysts expect the stock to reach $77.33 within the next 12 months. Verona Pharma Plc ADR [NASDAQ: VRNA] shares were valued at $62.01 at the most recent close of the market. An investor can expect a potential return of 24.71% based on the average VRNA price forecast.
Analyzing the VRNA fundamentals
Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -3.66%, Pretax Profit Margin comes in at -3.89%, and Net Profit Margin reading is -4.1%. To continue investigating profitability, this company’s Return on Assets is posted at -0.37, Equity is -0.95 and Total Capital is -0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 60.42 points at the first support level, and at 58.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 62.87, and for the 2nd resistance point, it is at 63.73.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Verona Pharma Plc ADR [NASDAQ:VRNA] is 10.63. On the other hand, the Quick Ratio is 10.48, and the Cash Ratio is 9.37. Considering the valuation of this stock, the price to sales ratio is 124.95, the price to book ratio is 25.65.
Transactions by insiders
Recent insider trading involved Rickard Kathleen A., Chief Medical Officer, that happened on Mar 12 ’25 when 79264.0 shares were sold. Officer, KATHLEEN RICKARD completed a deal on Mar 12 ’25 to buy 9908.0 shares. Meanwhile, President and CEO ZACCARDELLI DAVID sold 0.64 million shares on Dec 05 ’24.
